Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study

Documenti analoghi

• Oral decitabine–cedazuridine in acute myeloid leukaemia
  di: Ian M. Bouligny, et al.
  Pubblicazione: (2024)
• Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
  di: Michael R. Savona, et al.
  Pubblicazione: (2025)
• Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies
  di: Katherine Parks, et al.
  Pubblicazione: (2024)
• Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients
  di: Annie Im, et al.
  Pubblicazione: (2024)
• A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
  di: Sudhir Manda, et al.
  Pubblicazione: (2024)